Joshua E. Reuss
A5040159842- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Immune cells in cancer
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Myasthenia Gravis and Thymoma
- Peptidase Inhibition and Analysis
- Occupational and environmental lung diseases
- Melanoma and MAPK Pathways
- Gastric Cancer Management and Outcomes
- Dermatological and Skeletal Disorders
- Advanced Breast Cancer Therapies
- Skin Diseases and Diabetes
Georgetown University Medical Center
2020-2025
Georgetown University
2020-2025
MedStar Georgetown University Hospital
2021-2024
Georgetown Lombardi Comprehensive Cancer Center
2022-2024
Sidney Kimmel Comprehensive Cancer Center
2017-2024
Johns Hopkins University
2017-2023
Cleveland Clinic
2023
Johns Hopkins Medicine
2019-2023
MedStar Heart & Vascular Institute
2023
National Heart Lung and Blood Institute
2023
Abstract PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these cell responses. Single-cell transcriptomics have revealed global dysfunction programs tumour-infiltrating lymphocytes (TIL). However, majority of TIL do not recognize antigens 2 and little is known about transcriptional MANA-specific TIL. Here, we identify clones using MANA functional expansion assay 3 neoadjuvant...
We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate pathologic response. Building on these results, promising data for plus ipilimumab (anti-CTLA-4) advanced NSCLC, we expanded our study include arm investigating ipilimumab.Patients stage IB (≥4 cm)-IIIA (American Joint Committee Cancer Tumor Node Metastases seventh edition), histologically confirmed,...
Background Despite treatment advancements with immunotherapy, our understanding of response relies on tissue-based, static tumor features such as mutation burden (TMB) and programmed death-ligand 1 (PD-L1) expression. These approaches are limited in capturing the plasticity tumor–immune system interactions under selective pressure immune checkpoint blockade predicting therapeutic long-term outcomes. Here, we investigate relationship between serial assessment peripheral blood cell counts...
Neoadjuvant anti-PD-1 therapy has shown promise for resectable non-small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant nivolumab in NSCLC, finding it to be safe and feasible with encouraging major pathological responses (MPR). now present 5-year clinical outcomes from this trial, representing our knowledge, longest follow-up data any type.Two doses (3 mg/kg) were administered 4 weeks before surgery 21 patients Stage I-IIIA NSCLC. recurrence-free survival...
PURPOSE Immune checkpoint inhibitors (ICIs) have revolutionized the care of patients with cancer, but use among hospitalized is controversial as a result questionable benefit and high costs. To evaluate role ICIs in inpatient (IP) setting, we conducted Inpatient Immunotherapy Outcomes Study (IIOS) to describe characteristics outcomes who received IP ICIs. METHODS IIOS retrospective study treated during hospitalization between 2012 2021 at five academic institutions. Data collection was...
We report a case of sarcoidosis in patient with metastatic melanoma managed combination ipilimumab/nivolumab. Sarcoid development has been linked single agent immunotherapy but, to our knowledge, it not reported ipilimumab/nivolumab treatment. This raises unique management challenges for both the and immunotherapy-related toxicity.A 46 year old Caucasian female M1c-metastatic was combination. Patient experienced response baseline lesions but developed new clinical radiographic findings....
Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, outcomes not well described.We report the in an academic center were treated with ICIs from May to December 2017. Patient characteristics, toxicities, confirmed irAE admissions reported. Associations between patient features hospitalizations examined.Twenty-three percent (n = 100) 443 admitted oncology over 6 months had...
<p>Figure S1</p>
<div>AbstractPurpose:<p>Co-mutations of the <i>Kirsten rat sarcoma virus</i> (<i>KRAS</i>) and <i>serine</i>/<i>threonine kinase 11</i> (<i>STK11</i>) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant chemoimmunotherapy is now a standard-of-care treatment for resectable NSCLC, clinical immunologic impacts <i>KRAS</i>...
<p>Figure S4</p>
<p>Figure S5</p>
<p>Figure S6</p>
<p>Figure S3</p>
<p>Figure S2</p>
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual . follow Conflict of Interest Policy Implementation Clinical Practice and updates not intended to substitute independent professional judgment treating clinician do account...